Broadly, the abstract seems to be describing a particular cell-surface marker found to be associated with senescence ("seno-antigen") which can be targeted by a therapy ("genetic ablation") which accelerates removal of cells with that marker. Doing so improves the lifespan of mice so treated.
Thus, as the abstract concludes, "...vaccination targeting seno-antigens could be a potential strategy for new senolytic therapies."
https://www.reddit.com/r/science/comments/ren6cc/japanese_sc...
Making sure they actually get replaced with new cells instead of scar tissue is another.
Until that’s resolved, killing the wrong kinds of senescent cells will kill you much faster than leaving them alone, so even highly targeted killing of senescent cells can’t “rejuvenate” all your organs.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)...
Given N "advances" that you hear touted based on mouse trials, how many turn into real human therapies? (Curing aging in mice isn't really the advance we're looking for.) How many turn into real human therapies that live up to the breathless announcements that were made based on the mouse trials? I don't have hard evidence, but my gut estimate is 10-20% actually deliver.
So, yes, while waiting for the science, there is some empirical grounds to have a default stance of doubt (or, if you prefer, skepticism).
2) In science often abstracts or intros open with grand ideas before settling into a much smaller scope.
3) The rise of predatory journals, not to mention people citing pre-print arXivs means even if something looks likes a reasonable article, it's good to get the opinions of other experts.
4) Just because something works doesn't imply how practical it is for actual deployment. (I've been to plenty of chemical talks about fantastic polymers, I've only ever seen one turn into anything of value.)